Skip to main content
  • T7 Therapeutics
  • Investment: 2021
  • Status: Active

T7 Therapeutics plans to develop, a first-in-class monoclonal antibody targeting a broad set of autoimmune diseases to clinical proof-of-concept. This antibody targets a new critical pathway in autoimmunity, initially discovered by Nalân Utku during her training at the laboratories in Renal Division of Brigham and Women’s Hospital, Harvard Medical School. Humanized antibodies subsequently were developed at Nekonal S.a.r.l.

Involved Team

Marc Rivière, MD
General Partner,
Montreal
Dr. Sascha Berger
General Partner,
Munich

Caroline Fortier (CEO)